LAS VEGAS, April 30, 2014 /PRNewswire/ -- GrowBLOX Sciences,
Inc. (OTCQB: GBLX) CEO, Craig
Ellins, will be participating on a panel of thought
provoking industry leaders in the medicinal marijuana sector at the
Milken Institute Global Conference. The Milken Conference is
a prominent forum where investors from around the world, industry
and government leaders, experts and economists from diverse
industries analyze a myriad of issues facing global markets.
The conference aligns decision-makers from private and public
sectors in order to debate and discuss practical solutions for
prosperity and action around the globe.
This distinctive panel will focus on the legalization and social
implications that surround the legal marijuana industry, as well as
the vast business opportunities that are available in today's
marketplace. While the industry historically has had a
negative stigma attached to it – being until recently an
underground market – medicinal marijuana, now legal in 21 states,
is projected to become a $6 billion
industry by 2016.
The panel discussion: "The Highs – and Lows – of the Cannabis
Economy," will take place today, April 30,
2014 and will be moderated by Mike 'Zappy' Zapolin. Zappy is
a social entrepreneur recognized as one of the key industry leaders
in the cannabis economy. His company, Zappy Inc., is focused
on the life sciences opportunities, including new medical
applications and safe delivery. Other co-panelists include
DigiPath CEO, Todd Denkin, WeedMD RX
Chairman, Michael Kraft, National
Families in Action Inc. CEO, Sue
Rusche, and Goodwin Procter LLP legal expert, Doug Praw.
Ellins will provide details on the Company's proprietary growing
technology at the conference. The GrowBLOX controlled
environment agricultural chambers are designed to create a
consistent environment for each plant by controlling the light,
humidity, nutrition, temperature and aeration, while excluding
outside stresses like, pathogens and pests. All parameters
are pre-programmed for each unit and optimized for each cultivar,
ensuring the composition and yield from each batch will
consistently reflect the genetic makeup of the plants. The
GrowBLOX cultivation method will make it possible to reliably
provide products with very defined properties to patients with
specific needs.
For more information surrounding the proprietary growing
technology, please visit http://www.gbsciences.com.
For more information on the Milken Institute Global Conference,
please visit http://www.globalconference.org/.
About GrowBLOX Sciences, Inc.
GrowBLOX Sciences, Inc., is a research and biotechnical company
that has developed proprietary indoor growing chambers specifically
designed for medical cannabis cultivation. The GrowBLOX
chamber allows for completely controlled growing conditions,
ensuring the manufacture of a consistent, toxin-free, natural and
medicinal-grade product. The Company believes that the
advantages of a controlled environment over traditional outdoor or
greenhouse growing, will empower the public, nutraceutical and
pharmaceutical industries to embrace cannabis as an effective
treatment for a myriad of serious medical conditions.
http://www.gbsciences.com
Forward-Looking Statements
Except for historical information contained herein, the
statements in this release are forward-looking and made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are inherently
unreliable and actual results may differ materially. Examples of
forward-looking statements in this news release include statements
regarding the payment of dividends, marketing and distribution
plans, development activities and anticipated operating results.
Factors which could cause actual results to differ materially
from these forward-looking statements include such factors as the
Company's ability to accomplish its business initiatives,
significant fluctuations in marketing expenses and ability to
achieve and expand significant levels of revenues, or recognize net
income, from the sale of its products and services, as well as the
introduction of competing products, or management's ability to
attract and maintain qualified personnel necessary for the
development and commercialization of its planned products, and
other information that may be detailed from time to time in the
Company's filings with the United States Securities and Exchange
Commission. The Company undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Contact:
Craig Ellins
CEO, GrowBLOX Sciences, Inc.
+1-844-843-BLOX ext. 01
SOURCE GrowBLOX Sciences, Inc.